The use of glucocorticoids in rheumatoid arthritis - no rational approach yet 英文参考文献.docVIP

Desai and Solomon Arthritis Research Therapy 2010,12:127 /content/12/3/127 EDITORIAL The use of glucocorticoids in rheumatoid arthritis - no ‘rational’ approach yet Sonali P Desai* and Daniel H Solomon See related research by Ibanez et al., /content/12/2/R50 for the use of GCs in combination with other disease Abstract modifying anti-rheumatic drugs (DMARDs) to signi? - The relationship between glucocorticoids and bone mineral density in rheumatoid arthritis is complex. Further study into the optimal dosing, timing and duration of glucocorticoid use in rheumatoid arthritis is cantly reduce RA disease activity [5]. A subsequent review demonstrates that GCs (mean cumulative dose of 2,300 mg prednisone equivalent over the ? rst year), when used in combination with traditional DMARD therapy, necessary. can decrease the rate of radiographic progression in RA e e? ect of GCs on bone mass, among non-RA erapy, patients, has been evaluated in a small randomized, In the previous issue of Arthritis Research a Ibanez and colleagues [1] report on the ‘rational’ use of placebo-controlled trial demonstrating that serum gluco corticoids (GCs) in the management of early arthritis. is article concludes that GCs cause minimal varia tion in bone mineral density (BMD) at multiple skeletal sites, and in fact may increase BMD at the ultra distal forearm, a markers of bone formation are rapidly decreased among healthy post-menopausal women treated with just 5 mg of prednisone daily for 6 weeks [7]. In early RA patients treated with prednisolone 7.5 mg per day and traditional juxta-articular site. Although this article is notable for DMARD therapy (compared to traditional DMARD examining the e? ect of GCs on BMD at ? ve anatomic therapy alone), markers of bone formation, markers of sites, a ‘rational’ use of GCs for rheumatoid arthri